Article
Cellular plasticity and the neuroendocrine phenotype in prostate cancer.
Nature reviews. Urology - 1 May 2018
Davies Alastair H, Beltran Himisha, Zoubeidi Amina
Abstract excerpt
The success of next-generation androgen receptor (AR) pathway inhibitors, such as abiraterone acetate and enzalutamide, in treating prostate cancer has been hampered by the emergence of drug resistance. This acquired drug resistance is driven, in part, by the ability of prostate cancer cells to change their phenotype to adopt AR-independent pathways for growth and survival. Around one-quarter of resistant...
Topics
Join the communities discussing this publication.